| Literature DB >> 29879759 |
Yusuke Okuda1,2, Tomonori Yamada3, Yoshikazu Hirata2, Takaya Shimura1, Ryuzo Yamaguchi4, Eiji Sakamoto5, Satoshi Sobue2, Takahiro Nakazawa3, Hiromi Kataoka1, Takashi Joh1.
Abstract
PURPOSE: Since oncological outcomes of transanal colorectal tube (TCT) placement, an endoscopic treatment for colorectal cancer (CRC) with acute colorectal obstruction (ACO), remain unknown, this study analyzed long-term outcomes of TCT placement for stage II/III CRC with ACO.Entities:
Keywords: Acute colorectal obstruction; Bridge to surgery; Colorectal neoplasms; Emergency surgery; Transanal colorectal tube
Mesh:
Year: 2018 PMID: 29879759 PMCID: PMC6473272 DOI: 10.4143/crt.2018.059
Source DB: PubMed Journal: Cancer Res Treat ISSN: 1598-2998 Impact factor: 4.679
Fig. 1.Consort diagram. The Kasugai Municipal Hospital, Kasugai, Japan (K hospital) applied emergency surgery and the Nagoya Daini Red Cross Hospital, Nagoya, Japan (R hospital) applied transanal colorectal tube (TCT) as the standard treatment for colorectal cancer (CRC) with acute colorectal obstruction (ACO). A-colon, ascending colon.
Characteristics of patients with colorectal cancer
| Non-ACO cohort | ACO cohort | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All patients | Propensity score-matched patients | All patients | Propensity score-matched patients | |||||||||
| K hospital (n=234) | R hospital (n=446) | p-value | K hospital (n=234) | R hospital (n=446) | p-value | Surgery group (n=27) | TCT group (n=47) | p-value | Surgery group (n=23) | TCT group (n=23) | p-value | |
| 69 (62-75) | 70 (62-77) | 0.54[ | 69 (62-75) | 67 (60-74) | 0.20[ | 70 (64-75) | 71 (63-79) | 0.60[ | 70 (64-74) | 72 (63-81) | 0.54[ | |
| Male | 148 (63.2) | 258 (57.8) | 0.17[ | 148 (63.2) | 147 (62.8) | 0.92[ | 19 (70.4) | 31 (66.0) | 0.70[ | 16 (69.6) | 16 (69.6) | > 0.99[ |
| Female | 86 (36.8) | 188 (42.2) | 86 (36.8) | 87 (37.2) | 8 (29.6) | 16 (34.0) | 7 (30.4) | 7 (30.4) | ||||
| Rectum | 79 (33.8) | 122 (27.4) | 0.08[ | 79 (33.8) | 68 (29.1) | 0.27[ | 0 | 1 (2.1) | 0.64[ | 0 | 0 | > 0.99[ |
| Colon | 155 (66.2) | 324 (72.6) | 155 (66.2) | 166 (70.9) | 27 (100) | 46 (97.9) | 23 (100) | 23 (100) | ||||
| II | 119 (50.9) | 226 (50.7) | 0.96[ | 119 (50.9) | 110 (47.0) | 0.41[ | 15 (55.6) | 26 (55.3) | 0.98[ | 11 (47.8) | 11 (47.8) | > 0.99[ |
| III | 115 (49.1) | 220 (49.3) | 115 (49.1) | 124 (53.0) | 12 (44.4) | 21 (44.7) | 12 (52.2) | 12 (52.2) | ||||
| R0 | 232 (99.1) | 432 (96.9) | 0.06[ | 232 (99.1) | 230 (98.3) | 0.69[ | 27 (100) | 44 (93.6) | 0.25[ | 23 (100) | 23 (100) | > 0.99[ |
| R1 | 2 (0.9) | 14 (3.1) | 2 (0.9) | 4 (1.7) | 0 | 3 (6.4) | 0 | 0 | ||||
| No | 82 (35.0) | 240 (53.8) | < 0.001[ | 82 (35.0) | 92 (39.3) | 0.34[ | 10 (37.0) | 26 (55.3) | 0.13[ | 9 (39.1) | 9 (39.1) | > 0.99[ |
| Yes | 152 (65.0) | 206 (46.2) | 152 (65.0) | 142 (60.7) | 17 (63.0) | 21 (44.7) | 14 (60.9) | 14 (60.9) | ||||
| Oral fluoropyrimidine | 147 (96.7) | 195 (94.7) | 0.33[ | 147 (96.7) | 133 (93.7) | 0.22[ | 14 (82.4) | 18 (85.7) | > 0.99[ | 11 (78.6) | 13 (92.9) | 0.60[ |
| XELOX or FOLFOX | 5 (3.3) | 11 (5.3) | 5 (3.3) | 9 (6.3) | 3 (17.6) | 3 (14.3) | 3 (21.4) | 1 (7.1) | ||||
Values are presented as median (range) or number (%). ACO, acute colorectal obstruction; K hospital, Kasugai Municipal Hospital, Kasugai, Japan; R hospital, Nagoya Daini Red Cross Hospital, Nagoya, Japan; TCT, transanal colorectal tube; XELOX, oxaliplatin plus capecitabine; FOLFOX, oxaliplatin plus infusional 5-fluorouracil and leucovorin; IQR, interquartile range,
Mann-Whitney U test,
Chi-square test,
Fisher exact probability test.
Fig. 2.Overall survival (OS) (A) and disease-free survival (DFS) (B) for stage II/III colorectal cancer without acute colorectal obstruction. K hospital, Kasugai Municipal Hospital, Kasugai, Japan; R hospital, Nagoya Daini Red Cross Hospital, Nagoya, Japan.
Short-term outcome
| Surgery group (K hospital) (n=23) | TCT group (R hospital) (n=23) | p-value | |
|---|---|---|---|
| Technical success | 23/23 (100) | 23/23 (100) | > 0.99[ |
| Clinical success | 23/23 (100) | 22/23 (95.7) | > 0.99[ |
| Hospital stay (day) | 30 (16-40) | 36 (27-44) | 0.09[ |
| Anastomosis leakage | 0/23 (0.0) | 2/23 (8.7) | 0.49[ |
| Short-term mortality | 1/23 (4.3) | 0/23 (0.0) | > 0.99[ |
| Primary resection/anastomosis | 6/23 (26.1) | 20/23 (87.0) | < 0.001[ |
| Overall stoma | 17/23 (73.9) | 3/23 (13.0) | < 0.001[ |
| Permanent stoma | 2/23 (8.7) | 2/23 (8.7) | > 0.99[ |
| LAC | 0/23 (0.0) | 13/23 (56.5) | < 0.001[ |
Values are presented as number (%) or median (IQR). K hospital applied emergency surgery and R hospital applied TCT as the first-line standard treatment for CRC with ACO. K hospital, Kasugai Municipal Hospital, Kasugai, Japan; TCT, transanal colorectal tube; R hospital, Nagoya Daini Red Cross Hospital, Nagoya, Japan; LAC, laparoscopy-assisted colectomy; IQR, interquartile range.
Fisher exact probability test,
Mann-Whitney U test.
Fig. 3.Overall survival (OS) (A) and disease-free survival (DFS) (B) for stage II/III colorectal cancer with acute colorectal obstruction. Surgery group comprised patients with emergency surgery at Kasugai Municipal Hospital, Kasugai, Japan (K hospital) and transanal colorectal tube (TCT) group did patients with TCT at Nagoya Daini Red Cross Hospital, Nagoya, Japan (R hospital).